Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2023-05-26 Major Shareholding Noti…
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains an 'RNS Number'. It details changes in voting rights percentages (crossing a threshold from 5.50% to 4.88%) held by Unicorn Asset Management Limited in Fusion Antibodies plc. This type of filing, reporting changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2023-05-26 English
Result of Retail Offer and Notice of GM
Share Issue/Capital Change Classification · 99% confidence The document is identified by the header 'RNS Number : 2615A' and the date '23 May 2023'. It announces the 'Result of Retail Offer' and provides a 'Notice of General Meeting'. It details the gross proceeds raised (£113,351.10) and the total shares issued pursuant to the Fundraise. Crucially, it states: 'The Company will shortly be posting a Circular containing a notice of General Meeting...'. This structure—announcing the results of a capital raise and notifying shareholders about an upcoming General Meeting where resolutions related to the raise must be passed—is characteristic of corporate actions requiring shareholder approval. Since it announces the results of a vote/offer and provides notice for a meeting where voting will occur, it strongly relates to shareholder actions. The most specific category covering voting results is DVA (Declaration of Voting Results & Voting Rights Announcements), but since this document is primarily announcing the *results* of a capital raise contingent on a future vote, and also serves as the *notice* for that meeting, it touches upon both Capital/Financing (CAP) and AGM/Voting matters. However, the core purpose is announcing the outcome of the Retail Offer and providing the notice for the General Meeting required to complete it. Given the explicit mention of the 'Notice of General Meeting' and the context of shareholder voting on resolutions, it aligns closely with documents related to shareholder meetings and voting outcomes. Since it is a formal announcement via RNS detailing the outcome of a capital raise contingent on a future vote, and includes the notice for that meeting, it is best classified as a Regulatory Filing (RNS) or potentially related to Capital (CAP). Since it is a formal, non-financial results announcement distributed via the RNS system, and covers multiple corporate actions (fundraising result + meeting notice), RNS is a strong candidate. However, the content is highly specific to a capital raise and the subsequent meeting required to approve it. If we must choose a specific action, the announcement of the results of the offer and the notice for the meeting that approves it points towards a Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). Given the explicit mention of the General Meeting notice, it is a hybrid. Since it is a formal, non-financial report announcement distributed via RNS, and the content is about the result of a capital raise and the notice for the required shareholder vote, RNS is the most appropriate general regulatory category for this type of announcement that doesn't fit perfectly into ER, IR, or 10-K. It is a standard regulatory announcement. Revisiting the definitions: It is not a DEF 14A (Remuneration), not a DIV (Dividend), and not a DVA (which is for *results* of a vote, though this announces the *need* for one). It is a formal announcement of a capital raise result and a meeting notice. This fits best under RNS as a general regulatory announcement, or potentially CAP. Given the RNS header and the nature of the announcement (not a financial report itself), RNS is the safest classification.
2023-05-23 English
REX Retail Offer
Regulatory Filings Classification · 98% confidence The document is an official announcement from Fusion Antibodies PLC, identified by the RNS Number (0314A) and the date (19 May 2023). The content details a 'REX Retail Offer' of ordinary shares, a 'Placing' of shares, and a 'Subscription' for shares, all contingent on passing resolutions at a 'general meeting'. This announcement is clearly related to the issuance of new capital/securities and the associated shareholder vote required to approve it. Since it announces the terms of a share issuance/fundraising activity, it fits the 'Capital/Financing Update' (CAP) category. While it mentions a General Meeting, the primary focus is the capital raise itself, not the voting results (DVA) or the proxy materials (PSI). It is a primary announcement of a financing event, not a general regulatory filing fallback (RNS).
2023-05-19 English
Placing, Subscription and Retail Offer
Capital/Financing Update Classification · 98% confidence The document is an official announcement from Fusion Antibodies PLC, identified by the RNS Number and the date (19 May 2023). The primary subject is a 'Placing, Subscription and Retail Offer' designed to raise capital (c. £1.56 million plus potential retail funds) through the issue of new ordinary shares. This activity—raising funds through the issuance of new shares, involving placing, subscription by directors, and a retail offer—falls directly under the definition of a Capital/Financing Update. Although it mentions a General Meeting to approve resolutions, the core purpose and content focus on the financing event itself, not the meeting materials or results. Therefore, the most appropriate code is CAP.
2023-05-19 English
Block listing Interim Review
Share Issue/Capital Change Classification · 99% confidence The document is identified by the header 'RNS Number : 0081V' and contains boilerplate text referencing 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content itself is a 'Block admission six monthly return' detailing the status of employee share options over a specific period (2 October 2022 to 1 April 2023). This type of mandatory disclosure, which doesn't fit into specific financial reports (10-K, IR, ER) or corporate actions (DIV, CAP), is best classified as a general regulatory announcement. Since it is a specific regulatory filing that doesn't match other detailed categories, the fallback category 'RNS' (Regulatory Filings) is the most appropriate classification.
2023-04-03 English
Change of Registered Office
Regulatory Filings Classification · 99% confidence The document is very short (4106 characters) and its primary content is an announcement regarding a 'Change of registered office' for Fusion Antibodies PLC. It is formatted with an RNS Number (8500U) and includes standard disclaimers about RNS distribution, which is the news service of the London Stock Exchange. This type of administrative or minor corporate update that does not fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified as a general regulatory announcement or filing. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback category for miscellaneous, non-standard regulatory announcements.
2023-03-31 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.